Watchlist Price Alert

Sarepta Therapeutics Inc. (SRPT)

NASDAQ: SRPT · Real-Time Price · USD

20.99

-15.19 (-41.98%)

At close: Jun 16, 2025, 3:59 PM

21.95

4.57%

After-hours: Jun 16, 2025, 07:48 PM EDT

-41.98% (1D)

Bid	21.91
Market Cap	2.06B
Revenue (ttm)	2.23B
Net Income (ttm)	-248.39M
EPS (ttm)	-2.64
PE Ratio (ttm)	-7.95
Forward PE	5.43
Analyst	Buy

Ask	22.01
Volume	41,154,779
Avg. Volume (20D)	3,899,928
Open	21.26
Previous Close	36.18
Day's Range	18.30 - 21.55
52-Week Range	18.30 - 173.25
Beta	0.60

About SRPT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SRPT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SRPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 day ago New

Sarepta shares are trading lower after the company... Unlock content with Pro Subscription

1 week ago

+9.69%

Sarepta Therapeutics shares are trading higher after Scotiabank upgraded the stock from Sector Perform to Sector Outperform.

News

19 hours ago · youtube.com

Mizuho's Jared Holz on what is next for Sarepta after second death connected to gene therapy

Jared Holz, Mizuho, joins 'Fast Money' to talk the fallout for Sarepta after another death related to its muscular dystrophy gene therapy.

13 hours ago · seekingalpha.com

Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy

Sarepta Therapeutics, Inc. plunged over 47% after a second ELEVIDYS-related patient death, raising serious safety concerns and leading to trial suspensions. Despite the negative headlines and slashed ...

13 hours ago · accessnewswire.com

Sarepta Therapeutics Stock Alert: Investors of Sarepta May Have Legal Claims and Are Encouraged to Contact Kehoe Law Firm, P.C. - SRPT

PHILADELPHIA, PA / ACCESS Newswire / June 16, 2025 / Kehoe Law Firm, P.C. is investigating potential violations of federal securities laws and claims on behalf of investors of Sarepta Therapeutics, In...

14 hours ago · youtube.com

Sarepta's gene therapy medicine kills patient, CEO suspends full year guidance

CNBC's Angelica Peebles reports on the latest news regarding Sarepta.

15 hours ago · youtube.com

SRPT Down Near 9-Year Low, CSCO Upgrade, ROKU Using AMZN Ads

Sarepta Therapeutics (SRPT) sold off more than 40% after suspending its Elevidys Duchenne muscular dystrophy drug, which was linked to two fatal liver failure cases. Diane King Hall break takes a clos...

16 hours ago · zacks.com

SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion

Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.

16 hours ago · proactiveinvestors.com

Sarepta Therapeutics stock drops following second death linked to gene therapy Elevidys

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged almost 45% after the company disclosed the death of a second patient from acute liver failure linked with its experimental gene therapy Elevidys f...

16 hours ago · seekingalpha.com

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective for...